Neurodegeneration as an early event in the Pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy

Trial Profile

Neurodegeneration as an early event in the Pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest diabetic retinopathy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Brimonidine (Primary) ; Somatostatin (Primary)
  • Indications Diabetic retinopathy
  • Focus Therapeutic Use
  • Acronyms EUROCONDOR
  • Sponsors BCN Peptides
  • Most Recent Events

    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 23 Nov 2013 Accrual to date is 107% according to United Kingdom Clinical Research Network.
    • 19 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top